Announcements Trials
Browse Landscape

Status

Completed 5

Sponsor Class

INDUSTRY 5OTHER 3

Study Type

Interventional 59Observational 5Expanded_access 1

Sponsor

Cancer Type

Genitourinary 5

Conditions

Carcinoma, Renal Cell 5Financial Stress 2Coronary Artery Disease 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Observational × pazopanib × Clear all
NCT02184416 2026-02-27

ADONIS

Pfizer

Completed
554 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT01649778 2020-07-15

PRINCIPAL

Novartis

Completed
662 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT01446224 2015-03-27

Cardiovascular and Torsades de Pointes Monitoring for Pazopanib

GlaxoSmithKline

Completed
1 enrolled
Genitourinary

Carcinoma, Renal Cell, Coronary Artery Disease

NCT01381601 2013-05-13

Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)

GlaxoSmithKline

Completed
1 enrolled
Genitourinary

Financial Stress, Carcinoma, Renal Cell

NCT01381614 2013-05-13

Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)

GlaxoSmithKline

Completed
1 enrolled
Genitourinary

Financial Stress, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡